Valneva SE Analyst Call Transcript
Good day, and thank you for standing by. Welcome to Valneva Announces U.S. FDA approval of World's First Chikungunya Vaccine, IXCHIQ. (Operator Instructions) Please be advised that today's conference is being recorded. I would now like to hand the conference over to your first speaker today, Josh Drumm, VP, Global Investor Relations. Please go ahead.
Thank you, Nadia. Hello, and thank you for joining us. We're excited to discuss the recent FDA approval of IXCHIQ, the world's first chikungunya vaccine and the third vaccine the company has advanced from early development to commercialization. It's my pleasure to welcome you today. Please note that you can find our press release from Friday and the analyst presentation published earlier today available within the Investors section of our website.
I'm joined today by Valneva's CEO, Thomas Lingelbach; and Chief Medical Officer -- Chief Medical Officer, Juan Carlos Jaramillo, who will provide an overview of chikungunya and IXCHIQ, the market outlook and the ongoing planned
Access to All Earning Calls and Stock Analysis | |
30-Year Financial on one screen | |
All-in-one Stock Screener with unlimited filters | |
Customizable Stock Dashboard | |
Real Time Insider Trading Transactions | |
8,000+ Institutional investors’ 13F holdings | |
Powerful Excel Add-in and Google sheets Add-on | |
All data downloadable | |
Quick customer support | |
And much more... |